BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dhakal P, Giri S, Pathak R, Bhatt VR. Eculizumab in Transplant-Associated Thrombotic Microangiopathy. Clin Appl Thromb Hemost 2017;23:175-80. [DOI: 10.1177/1076029615599439] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Svec P, Elfeky R, Galimard J, Higham CS, Dalissier A, Quigg TC, Bueno Sanchez D, Han Lum S, Faraci M, Cole T, Pichler H, Benítez-carabante MI, Horakova J, Gonzalez -Vicent M, Yanir A, Fagioli F, Wölfl M, von der Weid N, Protheroe R, Krivan G, Speckmann C, James B, Avcin SL, Bertrand Y, Verna M, Riha P, Patrick K, Cesaro S, Kalwak K, Bierings M, Büchner J, Mellgren K, Prohászka Z, Neven B, Lankester A, Corbacioglu S. Use of eculizumab in children with allogeneic haematopoietic stem cell transplantation associated thrombotic microangiopathy - a multicentre retrospective PDWP and IEWP EBMT study. Bone Marrow Transplant 2022. [DOI: 10.1038/s41409-022-01852-x] [Reference Citation Analysis]
2 Shimizu S, Morohashi T, Kanezawa K, Yagasaki H, Takahashi S, Morioka I. Case Report: Successful Treatment With Anti-C5 Monoclonal Antibody in a Japanese Adolescent Who Developed Thrombotic Microangiopathy After Autologous Bone Marrow Transplantation for Malignant Lymphoma. Front Pediatr 2022;10:908183. [DOI: 10.3389/fped.2022.908183] [Reference Citation Analysis]
3 Zhang Z, Wang H, Qi J, Tang Y, Cai C, Zhou M, Pan T, Wu D, Han Y. Acute graft-versus-host disease increase risk and accuracy in prediction model of transplantation-associated thrombotic microangiopathy in patients with myelodysplastic syndrome. Ann Hematol 2022. [PMID: 35357522 DOI: 10.1007/s00277-022-04820-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Abudayyeh A, Wanchoo R. Kidney Disease Following Hematopoietic Stem Cell Transplantation. Adv Chronic Kidney Dis 2022;29:103-115.e1. [PMID: 35817518 DOI: 10.1053/j.ackd.2021.11.003] [Reference Citation Analysis]
5 Sharif MO, Leavis HL, van Paassen P, van Rhenen A, Timmermans SAMEG, Ton E, Laar JMV, Spierings J. Severe thrombotic microangiopathy after autologous stem cell transplantation in systemic sclerosis: a case report. Rheumatology (Oxford) 2021;60:e326-8. [PMID: 33711097 DOI: 10.1093/rheumatology/keab239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Gabr JB, Bilal H, Mirchia K, Perl A. The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy. J Investig Med High Impact Case Rep 2020;8:2324709620947266. [PMID: 32757799 DOI: 10.1177/2324709620947266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 E Stoll K, Lee L. Posterior reversible encephalopathy syndrome in a patient with hematopoietic stem cell transplant (HSCT)-associated thrombotic microangiopathy (TA-TMA). J Case Rep Images Oncology 2021;7:1-5. [DOI: 10.5348/100085z10ks2021cr] [Reference Citation Analysis]
8 Schoettler M, Lehmann LE, Margossian S, Lee M, Kean LS, Kao PC, Ma C, Duncan CN. Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort. Blood Adv 2020;4:2536-47. [PMID: 32516415 DOI: 10.1182/bloodadvances.2019001242] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 13.0] [Reference Citation Analysis]
9 Awidi M, Jain M, Baur R. Transplant-associated Thrombotic Microangiopathy Treated with Eculizumab and Romiplostim. Eur J Case Rep Intern Med 2021;8:002294. [PMID: 33768076 DOI: 10.12890/2021_002294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhang R, Zhou M, Qi J, Miao W, Zhang Z, Wu D, Han Y. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis. Front Immunol 2020;11:564647. [PMID: 33552043 DOI: 10.3389/fimmu.2020.564647] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
11 Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC, Wallace G, Nelson A, Bleesing J, Chima RS, Hirsch R, Ryan TD, Benoit S, Mizuno K, Warren M, Davies SM. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood 2020;135:1049-57. [PMID: 31932840 DOI: 10.1182/blood.2019004218] [Cited by in Crossref: 25] [Cited by in F6Publishing: 48] [Article Influence: 12.5] [Reference Citation Analysis]
12 Jarmoliński T, Rosa M, Puziewicz-Zmonarska A, Kałwak K. Short Course of Eculizumab May Be Effective in Dialysis-Dependent Transplantation-Associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation: A Case Report. Transplant Proc 2020;52:2544-7. [PMID: 32917392 DOI: 10.1016/j.transproceed.2020.08.040] [Reference Citation Analysis]
13 Hanna RM, Barsoum M, Vandross A, Kurtz I, Burwick R. Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition. Curr Opin Nephrol Hypertens 2019;28:278-87. [PMID: 30865166 DOI: 10.1097/MNH.0000000000000499] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
14 Finkel KW, Kala J. Thrombotic microangiopathy. Onco-Nephrology 2020. [DOI: 10.1016/b978-0-323-54945-5.00022-9] [Reference Citation Analysis]
15 Joseph C, Angelo JR, Laskin BL, Hingorani S. Hematopoietic cell transplant associated kidney injury. Onco-Nephrology 2020. [DOI: 10.1016/b978-0-323-54945-5.00020-5] [Reference Citation Analysis]
16 Bassil C. Chronic kidney disease, end-stage renal disease, and bone marrow transplant. Onco-Nephrology 2020. [DOI: 10.1016/b978-0-323-54945-5.00024-2] [Reference Citation Analysis]
17 García-martín E, Manrique-rodríguez S, Martínez Fernández-llamazares C, Goicoechea-diezhondino M, Álvarez-blanco O, García-morín M, Sanjurjo-sáez M. Variability in management and outcomes of therapy with eculizumab in atypical hemolytic uremic syndrome. Expert Opinion on Orphan Drugs 2019;7:525-33. [DOI: 10.1080/21678707.2019.1703108] [Reference Citation Analysis]
18 Tadic J, Mijuskovic M, Petrovic M, Obrencevic K, Terzic B, Rabrenovic V, Vavic N, Maksic Đ. Treatment Options in Patients Suffering from Hemolytic-Uremic Syndrome: the Serbian Military Medical Academy Experience. Serbian Journal of Experimental and Clinical Research 2019;0:000010247820190060. [DOI: 10.2478/sjecr-2019-0060] [Reference Citation Analysis]
19 Wall SA, Zhao Q, Yearsley M, Blower L, Agyeman A, Ranganathan P, Yang S, Wu H, Bostic M, Jaglowski S, Brammer JE, William B, Choe H, Mims AS, Penza S, Efebera Y, Devine S, Cataland S, Davies SM, Vasu S. Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD. Blood Adv. 2018;2:2619-2628. [PMID: 30327370 DOI: 10.1182/bloodadvances.2018020321] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 11.3] [Reference Citation Analysis]
20 Nozawa A, Ozeki M, Hori T, Kawamoto N, Hirayama M, Azuma E, Fukao T. A Heterozygous CFHR3-CFHR1 Gene Deletion in a Pediatric Patient With Transplant-associated Thrombotic Microangiopathy Who was Treated With Eculizumab. J Pediatr Hematol Oncol 2018;40:e544-6. [PMID: 28991129 DOI: 10.1097/MPH.0000000000000986] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
21 Zhou H, Hara H, Cooper DKC. The complex functioning of the complement system in xenotransplantation. Xenotransplantation 2019;26:e12517. [PMID: 31033064 DOI: 10.1111/xen.12517] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
22 Schoettler M, Duncan C, Lehmann L. Severe, persistent neurotoxicity after transplant-associated thrombotic microangiopathy in a pediatric patient despite treatment with eculizumab. Pediatr Transplant 2019;23:e13381. [PMID: 30828947 DOI: 10.1111/petr.13381] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
23 Kaplan SL. Meningococcal Serogroup B Vaccine Immunogenicity in High-Risk Groups: What Are the Implications? Pediatrics 2018;142. [DOI: 10.1542/peds.2018-0554] [Reference Citation Analysis]
24 Wanchoo R, Bayer RL, Bassil C, Jhaveri KD. Emerging Concepts in Hematopoietic Stem Cell Transplantation-Associated Renal Thrombotic Microangiopathy and Prospects for New Treatments. Am J Kidney Dis 2018;72:857-65. [PMID: 30146419 DOI: 10.1053/j.ajkd.2018.06.013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
25 Gavriilaki E, Sakellari I, Batsis I, Mallouri D, Bousiou Z, Vardi A, Yannaki E, Constantinou V, Tsompanakou A, Vadikoliou C, Kaloyannidis P, Bamihas G, Anagnostopoulos A. Transplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation. Clin Transplant 2018;32:e13371. [DOI: 10.1111/ctr.13371] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
26 Rudoni J, Jan A, Hosing C, Aung F, Yeh J. Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients. Eur J Haematol 2018;101:389-98. [PMID: 29920784 DOI: 10.1111/ejh.13127] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
27 Vakiti A, Singh D, Pilla R, Alhaj-Moustafa M, Fitzpatrick KW. Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab. J Oncol Pharm Pract. 2019;25:1011-1015. [PMID: 29768958 DOI: 10.1177/1078155218774895] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
28 Jodele S. Complement in Pathophysiology and Treatment of Transplant-Associated Thrombotic Microangiopathies. Semin Hematol 2018;55:159-66. [PMID: 30032753 DOI: 10.1053/j.seminhematol.2018.04.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
29 Horváth O, Kállay K, Csuka D, Mező B, Sinkovits G, Kassa C, Stréhn A, Csordás K, Sinkó J, Prohászka Z, Kriván G. Early Increase in Complement Terminal Pathway Activation Marker sC5b-9 Is Predictive for the Development of Thrombotic Microangiopathy after Stem Cell Transplantation. Biol Blood Marrow Transplant 2018;24:989-96. [PMID: 29339271 DOI: 10.1016/j.bbmt.2018.01.009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
30 Khosla J, Yeh AC, Spitzer TR, Dey BR. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies. Bone Marrow Transplant 2018;53:129-37. [DOI: 10.1038/bmt.2017.207] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 13.4] [Reference Citation Analysis]
31 Epperla N, Hemauer K, Hamadani M, Friedman KD, Kreuziger LB. Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy. Transfusion. 2017;57:2775-2781. [PMID: 28836275 DOI: 10.1111/trf.14263] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
32 Parolin M, Vidal E. Complications of therapeutic apheresis in pediatric kidney transplantation. Transfus Apher Sci 2017;56:510-4. [PMID: 28760487 DOI: 10.1016/j.transci.2017.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
33 Masias C, Vasu S, Cataland SR. None of the above: thrombotic microangiopathy beyond TTP and HUS. Blood 2017;129:2857-63. [PMID: 28416509 DOI: 10.1182/blood-2016-11-743104] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 11.0] [Reference Citation Analysis]
34 Jokiranta TS. HUS and atypical HUS. Blood. 2017;129:2847-2856. [PMID: 28416508 DOI: 10.1182/blood-2016-11-709865] [Cited by in Crossref: 159] [Cited by in F6Publishing: 166] [Article Influence: 31.8] [Reference Citation Analysis]
35 Ikeda T, Okumi M, Unagami K, Kanzawa T, Sawada A, Kawanishi K, Omoto K, Ishida H, Tanabe K. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab. Nephrology (Carlton). 2016;21 Suppl 1:35-40. [PMID: 26970541 DOI: 10.1111/nep.12768] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
36 Zwang NA, Ho B, Kanwar YS, Lewis B, Cusick M, Friedewald JJ, Gallon L. A case of atypical hemolytic uremic syndrome in a second renal transplant. J Nephrol 2018;31:165-72. [PMID: 28224376 DOI: 10.1007/s40620-016-0373-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
37 Dhakal P, Bhatt VR. Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy? Bone Marrow Transplant 2017;52:352-6. [PMID: 27775697 DOI: 10.1038/bmt.2016.253] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
38 Rosenthal J. Hematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatment. J Blood Med 2016;7:181-6. [PMID: 27621680 DOI: 10.2147/JBM.S102235] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
39 Jodele S, Dandoy CE, Myers KC, El-Bietar J, Nelson A, Wallace G, Laskin BL. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transfus Apher Sci. 2016;54:181-190. [PMID: 27156964 DOI: 10.1016/j.transci.2016.04.007] [Cited by in Crossref: 69] [Cited by in F6Publishing: 78] [Article Influence: 11.5] [Reference Citation Analysis]